Sarcoidose

Sara Castelo Branco; Karin Luz; Cândida Fernandes; Jorge Cardoso

doi:10.29021/spdv.74.1.512

Sara Castelo Branco Interna de Medicina Interna/Resident, Internal Medicine, Unidade Funcional de Medicina 4, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisboa, Portugal
Karin Luz Interna de Medicina Interna/Resident, Internal Medicine, Unidade Funcional de Medicina 4, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisboa, Portugal
Cândida Fernandes Assistente Hospitalar Graduada de Dermatovenereologia/Graduated Consultant, Dermatology, Serviço de Dermatologia e Venereologia, Hospital de Curry Cabral, Centro Hospitalar de Lisboa Central, Lisboa, Portugal
Jorge Cardoso Chefe de Serviço de Dermatovenereologia/Consultant Chief, Dermatology, Hospital de Curry Cabral, Serviço de Dermatologia e Venereologia, Centro Hospitalar de Lisboa Central, Lisboa, Portugal

DOI: https://doi.org/10.29021/spdv.74.1.512

Keywords: Granuloma, Sarcoidosis, Skin Diseases

Abstract

Sarcoidosis is an inflammatory multisystemic disease of unknown etiology, which is characterized by the formation of noncaseating granulomas in the organs involved, mainly lungs and intrathoracic lymph nodes. Skin involvement occurs in 25-35%; it is usually an early finding and it is an accessible and safe location for histopathological study. Cutaneous lesions may present with a variety of morphologies, including papules, nodules, plaques, and infiltrated scars. The diagnosis of sarcoidosis is supported by the recognition of compatible clinical, imagiological and histopathologic features, and the exclusion of other granulomatous disorders. Early diagnosis and systemic treatment could prevent future complications.

Downloads

Download data is not yet available.

References

Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year

study in a health maintenance organization. Am J Epidemiol.

; 145: 234-41.

English JC, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol. 2001; 44: 725-43.

Thomas KW, Hunninghake GW. Sarcoidosis. JAMA. 2003; 289: 3300-03.

Baughman RP, Lower EE, bu Bois RM. Sarcoidosis. Lancet 2003; 361: 1111-18.

Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997; 336: 1224-34.

Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, et al. Epidemiology of Sarcoidosis in Japan. Eur Respir

J. 2008; 31: 372.

Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiological study of

sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004; 170:1324-30.

Cox CE, Davis-Allen A, Judson MA. Sarcoidosis. Med Clin North Am. 2005; 89: 817-28.

Nunes H, Soler P, Valeyre D. Pulmonary sarcoidosis. Allergy. 2005; 60: 565-82.

Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. Mycobacterial catalase-peroxidase is a tissue

antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201:755-6.

Smith G, Brownell I, Sanchez M, Prystowsky S. Advances in the genetics of sarcoidosis. Clin Genet. 2008; 73: 401-12.

Sato H, Grutters JC, Pantelidis P, Mizzon AN, Ahmad T, Van Houte AJ, et al. HLA-DQB1*0201: a marker for good

prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002; 27: 406-1.

Agostini C, Adami F, Semenzato G. New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol.

; 12:71-6.

Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007; 357: 2153-65.

Ma Y, Gal A, Koss MN. The pathology of pulmonary sarcoidosis: update. Semin Diagn Pathol. 2007; 24: 150-61.

Myers JL, Tazelaar HD. Challenges in pulmonary fibrosis: 6-Problematic granulomatous lung disease. Thorax

; 63: 78-84.

Elgart ML. Cutaneous sarcoidosis: definitions and types of lesions. Clin Dermatol. 1986; 4: 35-45.

Katta R. Cutaneous sarcoidosis: a dermatologic masquerader. Am Fam Physician. 2002; 65:1581–4.

Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol. 2007; 25:276–87.

Yanardag, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients.

Respir Med. 2003; 97: 978-82.

Leonard AL. A case of sarcoidosis mimicking rhinophyma. J Drugs Dermatol. 2003; 2: 333-4.

Mangas C, Fernández-Figueras MT, Fité E, Fernández-Chico N, Sàbat M, Ferrándiz C. Clinical spectrum and

histological analysis of 32 cases of specific cutaneous sarcoidosis. J Cutan Pathol. 2006; 33: 772-7.

Young RJ 3rd, Gilson RT, Yanase D, Elston DM. Cutaneous sarcoidosis. Int J Dermatol 2001; 40: 249-53.

Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: a review for the pulmonologist. Chest. 2009; 136:

-96.

Albertini JG, Tyler W, Miller OF. Ulcerative sarcoidosis: case report and review of the literature. Arch Dermatol.

; 133: 215-21.

Lynch PJ, Sams WM Jr. Principles and practice of dermatology. New York:Churchill Livingstone;1996.

O'Regan A, Berman JS. Sarcoidosis. Ann Intern Med. 2012; 156: ITC5-1, ITC5-2, ITC5-3, ITC5-4, ITC5-5,

ITC5-6, ITC5-7, ITC5-8, ITC5-9, ITC5-10, ITC5-11, ITC5-12, ITC5-13, ITC5-14, ITC5-15; quiz ITC5-16.

Silverstein E, Pertschuk LP, Friedland J. Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proc Natl Acad Sci USA. 1979; 76: 6646-8.

Studdy Pr, Bird R. Serum angiotensin converting enzyme in sarcoidosis- its value in present clinical practice. Ann Clin Biochem. 1989; 26: 13-8.

Baughman RP. Pulmonary sarcoidosis. Clin Chest Med. 2004; 25: 521-30.

Pietinalho A, Ohmichi M, Lofroos AB, Hiraga Y, Selroos O. The prognosis of sarcoidosis in Finland and Hokkaido,

Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis. 2000;

:158-66.

Gronhagen-Riska C, Selroos O, Niemisto M. Angiotensin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respire Dis. 1980; 61: 113-22.

Baughman RP, Ploysongsang Y, Roberts RD, Srivastava L. Effects of sarcoid and steroids on angiotensin-converting enzyme. Am Rev Respir Dis. 1983; 128: 631-3.

Deremee RA. Sarcoidosis. Mayo Clin Proc. 1995; 70: 177-81.

Scadding JG. Prognosis of intrathoracic sarcoidosis in England. BMJ. 1961; 4: 1165-72.

Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011; 183: 573-81.

Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung. 1987; 165: 371.

Koyama T, Ueda H, Togashi K, Umeoka S, Kataoka M, Nagai S. Radiologic manifestations in various organs. Radiographics. 2004; 24: 87-104.

Roberts SD, Mirowski GW, Wilkes D, Teague SD, Knox KS. Sarcoidosis. Part I: pulmonar manifestations. J Am Acad Dermatol. 2004; 51: 448-51.

Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose

positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007; 132: 1949-53.

Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of

patients in a case control study of sarcoidosis. Am J Respire Crit Care Med. 2001; 164: 1885-9.

Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012; 185: 1004-14.

de Boer S, Milne DG, Zeng I, Wilsher ML. Does CT scanning predict the likelihood of a positive transbronchial

biopsy in sarcoidosis? Thorax. 2009; 64: 436-9.

Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline:

the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zeland and the Irish

Thoracic Society. Thorax. 2008; 63 Suppl 5:v1-58.

Bjermer L, Thunell M, Rosenhall L, Sternberg N. Endobronchial biopsy positive sarcoidosis: relation to bronchoalveolar lavage and course of disease. Respir Med. 1991; 85: 229-34.

Haimovic A, Sanchez M, Judson MA, PrystowskyS. Sarcoidosis: a comprehensive review and update for the dermatologist: part II. Extracutaneous disease. J Am Acad Dermatol. 2012; 66: 719.e1-10.

Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol. 2007; 56: 69-83.

Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999 14: 1117-22.

Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3:

-407.

Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003; 124: 2023-6.

Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005; 127:1064-71.

Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B. Effect of the TNF-a inhibitor adalimumab in

patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012; 6:

-47.

Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012; 250:713-20.

Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001; 137: 69-73.

Wasfi Y, Rose C, Murphy J, Silveira L, Grutters J, Inoue Y, et al. A new tool to assess sarcoidosis severity. Chest.

; 129: 1234-45.